Clinuvel Pharmaceuticals Ltd

CUV

Company Profile

  • Business description

    Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

  • Contact

    535 Bourke Street
    Level 22
    MelbourneVIC3000
    AUS

    T: +61 396604900

    https://www.clinuvel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    16

Clinuvel Pharmaceuticals Ltd News & Analysis

stocks

Undervalued ASX biotech

Despite improving prospects the shares continue to sell off.
stocks

Undervalued ASX listed biotech refocuses

Fair value uneffected by suspended early-stage clinical trials.
funds

10 reasons many fund managers are now blank spaces

It looks easy from the outside, but asset management is a tough game. Winners can win big, but there are far more strugglers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,917.1081.90-0.91%
CAC 407,546.16225.81-2.91%
DAX 4023,425.97639.50-2.66%
Dow JONES (US)43,588.58542.40-1.23%
FTSE 1009,068.5864.23-0.70%
HKSE24,507.81265.52-1.07%
NASDAQ20,650.13472.31-2.24%
Nikkei 22540,799.60270.22-0.66%
NZX 50 Index12,729.4094.34-0.74%
S&P 5006,238.01101.38-1.60%
S&P/ASX 2008,662.0080.80-0.92%
SSE Composite Index3,559.9513.26-0.37%

Market Movers